BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/8/2015 2:17:00 PM | Browse: 1325 | Download: 2309
Publication Name World Journal of Hepatology
Manuscript ID 12944
Country Taiwan
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Optimal combination of antiangiogenic therapy for hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Hui-Ju Ch’ang
Funding Agency and Grant Number
Funding Agency Grant Number
National Health Research Institutes, Taiwan
Corresponding Author Hui-Ju Ch’ang, MD, National Institute of Cancer Research, National Health Research Institutes, R1-2034, 35, Keyen Road, Miaoli 35053, Taiwan. hjmc@nhri.org.tw
Key Words Antiangiogenesis; Hepatocellular carcinoma; Biomarker; Cytokines; Dynamic contrast enhanced magnetic resonance imaging
Core Tip Antiangiogenic therapy has become an important component of treatment in hepatocellular carcinoma (HCC) patients. However, traditional anatomic imaging of tumor shrinkage is not appropriate to evaluate the efficacy of antiangiogenesis achieved by normalizing tumor vasculature and systemic suppression of angiogenic and inflammatory cytokines. To identify and validate potential response biomarkers, standardized systemic, circulating, tissue and imaging assays should be incorporated in to preclinical and clinical studies regarding the combination of antiangiogenic agents to cytotoxic or biologic agents. The optimal dosage, schedule and duration of antiangiogenic during com-bination therapy for HCC patients should be titrated according to these response biomarkers.
Publish Date 2015-08-08 14:17
Citation Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040
URL http://www.wjgnet.com/1948-5182/full/v7/i16/2029.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i16.2029
Full Article (PDF) WJH-7-2029.pdf
Full Article (Word) WJH-7-2029.doc